Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.59 -1.05 (-0.86%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.13 PB Ratio: 1.76 GF Score: 85/100

Jazz Pharmaceuticals PLC Update on Rylaze Investor Webcast Transcript

Jul 20, 2021 / 08:30PM GMT
Release Date Price: $175.31 (+2.23%)
Operator

Thank you for standing by, and welcome to the Jazz Pharmaceuticals Rylaze Investor Update Conference Call. (Operator Instructions) As a reminder, today's call is being recorded.

I would now like to turn the conference to your host, Ms. Andrea Flynn. Ma'am, you may begin.

Andrea N. Flynn
Jazz Pharmaceuticals plc - VP & Head of IR

Thank you. Good afternoon, everyone, and thank you for joining us today for a discussion on the FDA approval and U.S. commercial launch of Rylaze, formerly known as JZP-458. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also reference the press release we issued on June 30 regarding the FDA approval of Rylaze.

On the webcast today are Bruce Cozadd, Chairman and Chief Executive Officer; Dr. Rob Iannone, Executive Vice President of R&D and Chief Medical Officer; and Kim Sablich, Executive Vice President and General Manager of North America. We're also pleased to have an external pediatric oncologist, Dr. Luke Maese from the University of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot